FDA approves a prefilled syringe format for Purified Cortrophin Gel, reducing administration steps for patients with inflammatory and autoimmune conditions.
ANI Pharmaceuticals has received FDA approval for a prefilled syringe format for Purified Cortrophin Gel, designed to simplify administration for patients. The drug is indicated for various conditions including acute exacerbations of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, among others. However, caution is advised for patients with comorbid conditions and during pregnancy due to potential risks.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
